-
1
-
-
84857355243
-
Effect of HLA DR epitope de-immunizaton of Factor VIII in vitro and in vivo
-
Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. Effect of HLA DR epitope de-immunizaton of Factor VIII in vitro and in vivo. Clin. Immunol. 142(3), 320-331 (2012).
-
(2012)
Clin. Immunol.
, vol.142
, Issue.3
, pp. 320-331
-
-
Moise, L.1
Song, C.2
Martin, W.D.3
Tassone, R.4
De Groot, A.S.5
Scott, D.W.6
-
3
-
-
40449085408
-
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
-
Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin. Exp. Immunol. 152(1), 138-146 (2008).
-
(2008)
Clin. Exp. Immunol.
, vol.152
, Issue.1
, pp. 138-146
-
-
Joseph, A.1
Munroe, K.2
Housman, M.3
Garman, R.4
Richards, S.5
-
4
-
-
84855542158
-
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
-
Messinger YH, Mendelsohn NJ, Rhead W et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 14(1), 135-142 (2012).
-
(2012)
Genet. Med.
, vol.14
, Issue.1
, pp. 135-142
-
-
Messinger, Y.H.1
Mendelsohn, N.J.2
Rhead, W.3
-
5
-
-
66749108874
-
Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy
-
Kubisz P, Plamenová I, Hollý P, Stasko J. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy. Med. Sci. Monit. 15(6), CS105-CS111 (2009).
-
(2009)
Med. Sci. Monit.
, vol.15
, Issue.6
-
-
Kubisz, P.1
Plamenová, I.2
Hollý, P.3
Stasko, J.4
-
6
-
-
0036277088
-
A personal history of the CAMPATH-1H antibody
-
Waldmann H. A personal history of the CAMPATH-1H antibody. Med. Oncol. 19 (Suppl.), S3-S9 (2002).
-
(2002)
Med. Oncol.
, vol.19
, Issue.SUPPL.
-
-
Waldmann, H.1
-
7
-
-
84934443957
-
Use of IMGT(-) databases and tools for antibody engineering and humanization
-
Lefranc MP, Ehrenmann F, Ginestoux C, Giudicelli V, Duroux P. Use of IMGT(-) databases and tools for antibody engineering and humanization. Methods Mol. Biol. 907, 3-37 (2012).
-
(2012)
Methods Mol. Biol.
, vol.907
, pp. 3-37
-
-
Lefranc, M.P.1
Ehrenmann, F.2
Ginestoux, C.3
Giudicelli, V.4
Duroux, P.5
-
8
-
-
77957361348
-
Development trends for human monoclonal antibody therapeutics
-
Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9(10), 767-774 (2010).
-
(2010)
Nat. Rev. Drug Discov.
, vol.9
, Issue.10
, pp. 767-774
-
-
Nelson, A.L.1
Dhimolea, E.2
Reichert, J.M.3
-
9
-
-
84864116473
-
Production of human or humanized antibodies in mice
-
Laffleur B, Pascal V, Sirac C, Cogné M. Production of human or humanized antibodies in mice. Methods Mol. Biol. 901, 149-159 (2012).
-
(2012)
Methods Mol. Biol.
, vol.901
, pp. 149-159
-
-
Laffleur, B.1
Pascal, V.2
Sirac, C.3
Cogné, M.4
-
10
-
-
0033866627
-
Antibody humanization: A case of the 'Emperor's new clothes'? Immunol
-
Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today 21(8), 397-402 (2000).
-
(2000)
Today
, vol.21
, Issue.8
, pp. 397-402
-
-
Clark, M.1
-
11
-
-
54049088585
-
Activation of natural regulatory T cells by IgG Fc-derived peptide "tregitopes"
-
De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112(8), 3303-3311 (2008).
-
(2008)
Blood
, vol.112
, Issue.8
, pp. 3303-3311
-
-
De Groot, A.S.1
Moise, L.2
McMurry, J.A.3
-
12
-
-
63749128279
-
Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics
-
De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin. Immunol. 131(2), 189-201 (2009).
-
(2009)
Clin. Immunol.
, vol.131
, Issue.2
, pp. 189-201
-
-
De Groot, A.S.1
Martin, W.2
-
13
-
-
84880992500
-
Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se
-
Su Y, Rossi R, De Groot AS, Scott DW. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J. Leukoc. Biol. 94(2), 377-383 (2013).
-
(2013)
J. Leukoc. Biol.
, vol.94
, Issue.2
, pp. 377-383
-
-
Su, Y.1
Rossi, R.2
De Groot, A.S.3
Scott, D.W.4
-
14
-
-
84872616027
-
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity
-
Cousens LP, Najafian N, Mingozzi F et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity. J. Clin. Immunol. 33(1), 43-49 (2013).
-
(2013)
J. Clin. Immunol.
, vol.33
, Issue.1
, pp. 43-49
-
-
Cousens, L.P.1
Najafian, N.2
Mingozzi, F.3
-
15
-
-
77953658260
-
The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions
-
Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2(3), 256-265 (2010).
-
(2010)
MAbs.
, vol.2
, Issue.3
, pp. 256-265
-
-
Harding, F.A.1
Stickler, M.M.2
Razo, J.3
Dubridge, R.B.4
-
16
-
-
0030008601
-
Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients
-
McIntyre JA, Kincade M, Higgins NG. Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients. Transplantation 61(10), 1465-1469 (1996).
-
(1996)
Transplantation
, vol.61
, Issue.10
, pp. 1465-1469
-
-
McIntyre, J.A.1
Kincade, M.2
Higgins, N.G.3
-
17
-
-
0033387144
-
Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor
-
Uckun FM, Messinger Y, Chen CL et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin. Cancer Res. 5(12), 3906-3913 (1999).
-
(1999)
Clin. Cancer Res.
, vol.5
, Issue.12
, pp. 3906-3913
-
-
Uckun, F.M.1
Messinger, Y.2
Chen, C.L.3
-
18
-
-
0035478728
-
Pivotal study of iodine i 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
-
Kaminski MS, Zelenetz AD, Press OW et al . Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19(19), 3918-3928 (2001).
-
(2001)
J. Clin. Oncol.
, vol.19
, Issue.19
, pp. 3918-3928
-
-
Kaminski, M.S.1
Zelenetz, A.D.2
Press, O.W.3
-
19
-
-
0033624181
-
Safety and biodistribution of 99mTechnetium-labeled anti- CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients
-
Stroomer JW, Roos JC, Sproll M et al. Safety and biodistribution of 99mTechnetium-labeled anti- CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 6(8), 3046-3055 (2000).
-
(2000)
Clin. Cancer Res.
, vol.6
, Issue.8
, pp. 3046-3055
-
-
Stroomer, J.W.1
Roos, J.C.2
Sproll, M.3
-
20
-
-
0033855660
-
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
-
Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135-3143 (2000).
-
(2000)
J. Clin. Oncol.
, vol.18
, Issue.17
, pp. 3135-3143
-
-
Davis, T.A.1
Grillo-López, A.J.2
White, C.A.3
-
21
-
-
0032791210
-
Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
-
Piro LD, White CA, Grillo-López AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10(6), 655-661 (1999).
-
(1999)
Ann. Oncol.
, vol.10
, Issue.6
, pp. 655-661
-
-
Piro, L.D.1
White, C.A.2
Grillo-López, A.J.3
-
22
-
-
25444437442
-
Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study
-
Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52(9), 2740-2750 (2005).
-
(2005)
Arthritis Rheum.
, vol.52
, Issue.9
, pp. 2740-2750
-
-
Pijpe, J.1
Van Imhoff, G.W.2
Spijkervet, F.K.3
-
23
-
-
4043179907
-
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
-
Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580-2589 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.8
, pp. 2580-2589
-
-
Looney, R.J.1
Anolik, J.H.2
Campbell, D.3
-
24
-
-
84867838679
-
Humanization by CDR grafting and specificity-determining residue grafting
-
M Kim JH, Hong HJ. Humanization by CDR grafting and specificity- determining residue grafting. Methods Mol. Biol. 907, 237-245 (2012).
-
(2012)
Methods Mol. Biol.
, vol.907
, pp. 237-245
-
-
Kim, J.H.M.1
Hong, H.J.2
-
25
-
-
0041303578
-
Immunogenicity of biological therapeutics: A hierarchy of concerns
-
Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112, 15-21 (2003).
-
(2003)
Dev. Biol. (Basel)
, vol.112
, pp. 15-21
-
-
Rosenberg, A.S.1
-
26
-
-
79953681018
-
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters
-
Barbosa MD. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 16, 345-353 (2011).
-
(2011)
Drug Discov. Today
, vol.16
, pp. 345-353
-
-
Barbosa, M.D.1
-
27
-
-
84879975984
-
Drug monitoring of biologics in inflammatory bowel disease
-
Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr. Opin. Gastroenterol. 29(4), 391-396 (2013).
-
(2013)
Curr. Opin. Gastroenterol.
, vol.29
, Issue.4
, pp. 391-396
-
-
Eser, A.1
Primas, C.2
Reinisch, W.3
-
28
-
-
34249684926
-
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
-
Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555-561 (2007).
-
(2007)
Nat. Biotechnol.
, vol.25
, pp. 555-561
-
-
Shankar, G.1
Pendley, C.2
Stein, K.E.3
-
29
-
-
0042510222
-
Epoetins: Differences and their relevance to immunogenicity
-
Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr. Med. Res. Opin. 19(5), 430-432 (2003).
-
(2003)
Curr. Med. Res. Opin.
, vol.19
, Issue.5
, pp. 430-432
-
-
Haselbeck, A.1
-
30
-
-
0038752054
-
Pure red-cell aplasia due to anti-erythropoietin antibodies
-
Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant 18, 865-869 (2003).
-
(2003)
Nephrol. Dial. Transplant
, vol.18
, pp. 865-869
-
-
Eckardt, K.U.1
Casadevall, N.2
-
31
-
-
0347297138
-
A threshold for central T cell tolerance to an inducible serum 870 protein
-
Haribhai D, Engle D, Meyer M et al. A threshold for central T cell tolerance to an inducible serum 870 protein. J. Immunol. 170(6), 3007-3014 (2003).
-
(2003)
J. Immunol.
, vol.170
, Issue.6
, pp. 3007-3014
-
-
Haribhai, D.1
Engle, D.2
Meyer, M.3
-
32
-
-
58149381758
-
Elimination of antibodies to recombinant enzyme in pompe's disease
-
Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in pompe's disease. N. Engl. J. Med. 360(2), 194-195 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, Issue.2
, pp. 194-195
-
-
Mendelsohn, N.J.1
Messinger, Y.H.2
Rosenberg, A.S.3
Kishnani, P.S.4
-
33
-
-
4344627627
-
Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease
-
Garman RD, Munroe K, Richards SM. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin. Exp. Immunol. 137(3), 496-502 (2004).
-
(2004)
Clin. Exp. Immunol.
, vol.137
, Issue.3
, pp. 496-502
-
-
Garman, R.D.1
Munroe, K.2
Richards, S.M.3
-
34
-
-
77956613455
-
Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics
-
Wullner D, Zhou L, Bramhall E et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin. Immunol. 137(1), 5-14 (2010).
-
(2010)
Clin. Immunol.
, vol.137
, Issue.1
, pp. 5-14
-
-
Wullner, D.1
Zhou, L.2
Bramhall, E.3
-
35
-
-
29444451997
-
Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity
-
Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 118, 42-50 (2006).
-
(2006)
Clin. Immunol.
, vol.118
, pp. 42-50
-
-
Barbosa, M.D.1
Vielmetter, J.2
Chu, S.3
Smith, D.D.4
Jacinto, J.5
-
36
-
-
84887281589
-
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
-
(In Press)
-
Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clinical Immunology. (In Press).
-
Clinical Immunology
-
-
Jawa, V.1
Cousens, L.P.2
Awwad, M.3
Wakshull, E.4
Kropshofer, H.5
De Groot, A.S.6
-
37
-
-
42949139524
-
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach
-
Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 4(4), e1000048 (2008).
-
(2008)
PLoS Comput. Biol.
, vol.4
, Issue.4
-
-
Wang, P.1
Sidney, J.2
Dow, C.3
Mothé, B.4
Sette, A.5
Peters, B.6
-
38
-
-
34249010944
-
Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein
-
Koren E, De Groot AS, Jawa V et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124(1), 25-32 (2007).
-
(2007)
Clin. Immunol.
, vol.124
, Issue.1
, pp. 25-32
-
-
Koren, E.1
De Groot, A.S.2
Jawa, V.3
-
39
-
-
77955364125
-
A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: Individualized T cell epitope measure (iTEM)
-
Cohen T, Moise L, Ardito M, Martin W, De Groot AS. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J. Biomed. Biotechnol. 7 (2010).
-
(2010)
J. Biomed. Biotechnol.
, vol.7
-
-
Cohen, T.1
Moise, L.2
Ardito, M.3
Martin, W.4
De Groot, A.S.5
-
40
-
-
39649109499
-
Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion
-
Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol. 27(6), 620-627 (2007).
-
(2007)
J. Clin. Immunol.
, vol.27
, Issue.6
, pp. 620-627
-
-
Tatarewicz, S.M.1
Wei, X.2
Gupta, S.3
Masterman, D.4
Swanson, S.J.5
Moxness, M.S.6
-
42
-
-
0028295047
-
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
-
Kast WM, Brandt RM, Sidney J et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152, 3904-3912 (1994).
-
(1994)
J. Immunol.
, vol.152
, pp. 3904-3912
-
-
Kast, W.M.1
Brandt, R.M.2
Sidney, J.3
-
43
-
-
0032210911
-
Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix
-
Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 16(19), 1880-1884 (1998).
-
(1998)
Vaccine
, vol.16
, Issue.19
, pp. 1880-1884
-
-
Schafer, J.R.1
Jesdale, B.M.2
George, J.A.3
Kouttab, N.M.4
De Groot, A.S.5
-
44
-
-
0035859982
-
From genome to vaccine: In silico predictions, ex vivo verification
-
De Groot AS, Bosma A, Chinai N et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19(31), 4385-4395 (2001).
-
(2001)
Vaccine
, vol.19
, Issue.31
, pp. 4385-4395
-
-
De Groot, A.S.1
Bosma, A.2
Chinai, N.3
-
45
-
-
0034845973
-
Rapid determination of HLA B07 ligands from the West Nile virus NY99 genome
-
De Groot AS, Saint-Aubin C, Bosma A, Sbai H, Rayner J, Martin W. Rapid determination of HLA B07 ligands from the West Nile virus NY99 genome. Emerg. Infect. Dis. 7(4), 706-713 (2001).
-
(2001)
Emerg. Infect. Dis.
, vol.7
, Issue.4
, pp. 706-713
-
-
De Groot, A.S.1
Saint-Aubin, C.2
Bosma, A.3
Sbai, H.4
Rayner, J.5
Martin, W.6
-
46
-
-
33746132748
-
A consensus epitope prediction approach identifies the breadth of murine T(CD8+)- cell responses to vaccinia virus
-
Moutaftsi M, Peters B, Pasquetto V et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)- cell responses to vaccinia virus. Nat. Biotechnol. 24(7), 817-819 (2006).
-
(2006)
Nat. Biotechnol.
, vol.24
, Issue.7
, pp. 817-819
-
-
Moutaftsi, M.1
Peters, B.2
Pasquetto, V.3
-
48
-
-
84873587155
-
Structure-guided deimmunization of therapeutic proteins
-
Parker AS, Choi Y, Griswold KE, Bailey-Kellogg C. Structure-guided deimmunization of therapeutic proteins. J. Comput. Biol. 20(2), 152-165 (2013).
-
(2013)
J. Comput. Biol.
, vol.20
, Issue.2
, pp. 152-165
-
-
Parker, A.S.1
Choi, Y.2
Griswold, K.E.3
Bailey-Kellogg, C.4
-
49
-
-
64949147977
-
Deimmunization of monoclonal antibodies
-
Jones TD, Crompton LJ, Carr FJ, Baker MP. Deimmunization of monoclonal antibodies. Methods Mol. Biol. 525, 405-423 (2009).
-
(2009)
Methods Mol. Biol.
, vol.525
, pp. 405-423
-
-
Jones, T.D.1
Crompton, L.J.2
Carr, F.J.3
Baker, M.P.4
-
50
-
-
33644634447
-
De-immunization of therapeutic proteins by T-cell epitope modification
-
De Groot AS, Knopf PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 122, 171-194 (2005).
-
(2005)
Dev. Biol. (Basel)
, vol.122
, pp. 171-194
-
-
De Groot, A.S.1
Knopf, P.M.2
Martin, W.3
-
51
-
-
84887281859
-
Immunogenic biologics: Validation of screening, deimmunization and tolerization approaches (P3251)
-
Cousens L, Moise L, Terry F, Martin W, De Groot AS. Immunogenic biologics: validation of screening, deimmunization and tolerization approaches (P3251). J. Immunol. 190, 192 (2013).
-
(2013)
J. Immunol.
, vol.190
, pp. 192
-
-
Cousens, L.1
Moise, L.2
Terry, F.3
Martin, W.4
De Groot, A.S.5
-
53
-
-
0035063692
-
Challenges to the development of antigen-specific breast cancer vaccines
-
Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 3(2), 95-98 (2001).
-
(2001)
Breast Cancer Res.
, vol.3
, Issue.2
, pp. 95-98
-
-
Scanlan, M.J.1
Jager, D.2
-
54
-
-
0026691509
-
Viral escape from immune recognition: Multiple strategies of adenoviruses
-
Mullbacher A. Viral escape from immune recognition: multiple strategies of adenoviruses. Immunol. Cell Biol. 70(Pt 1), 59-63 (1992).
-
(1992)
Immunol. Cell Biol.
, vol.70
, Issue.PART 1
, pp. 59-63
-
-
Mullbacher, A.1
-
55
-
-
0031590291
-
Genetic analysis of host-parasite coevolution in human malaria
-
Hill AV, Jepson A, Plebanski M, Gilbert SC. Genetic analysis of host-parasite coevolution in human malaria. Philos. Trans. R. Soc. Lond. B Biol. Sci. 352(1359), 1317-1325 (1997).
-
(1997)
Philos. Trans. R. Soc. Lond. B Biol. Sci.
, vol.352
, Issue.1359
, pp. 1317-1325
-
-
Hill, A.V.1
Jepson, A.2
Plebanski, M.3
Gilbert, S.C.4
-
56
-
-
0036449295
-
Viral immune evasion: A masterpiece of evolution
-
Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. Viral immune evasion: a masterpiece of evolution. Immunogenetics 54(8), 527-542 (2002).
-
(2002)
Immunogenetics
, vol.54
, Issue.8
, pp. 527-542
-
-
Vossen, M.T.1
Westerhout, E.M.2
Soderberg-Naucler, C.3
Wiertz, E.J.4
-
57
-
-
23844439692
-
Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII
-
Jones TD, Phillips WJ, Smith BJ et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J. Thromb. Haemost. 3, 991-1000 (2005).
-
(2005)
J. Thromb. Haemost.
, vol.3
, pp. 991-1000
-
-
Jones, T.D.1
Phillips, W.J.2
Smith, B.J.3
-
58
-
-
0032812899
-
Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
-
Gilles JG, Lavend'homme R, Peerlinck K et al. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb. Haemost. 82, 40-45 (1999).
-
(1999)
Thromb. Haemost.
, vol.82
, pp. 40-45
-
-
Gilles, J.G.1
Lavend'Homme, R.2
Peerlinck, K.3
-
59
-
-
11844305190
-
Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation)
-
Hellendoorn K, Jones T, Watkins J, Baker M, Hamilton A, Carr F. Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation). Association for Immunotherapy of Cancer: Cancer Immunotherapy-2nd Annual Meeting Mainz, Germany. Cancer Cell Int. 4(Suppl. 1), S20 (2004).
-
(2004)
Association for Immunotherapy of Cancer: Cancer Immunotherapy-2nd Annual Meeting Mainz, Germany. Cancer Cell Int.
, vol.4
, Issue.SUPPL. 1
-
-
Hellendoorn, K.1
Jones, T.2
Watkins, J.3
Baker, M.4
Hamilton, A.5
Carr, F.6
-
60
-
-
20144384746
-
Rationally engineered therapeutic proteins with reduced immunogenicity
-
Tangri S, Mothe BR, Eisenbraun J et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174(6), 3187-3196 (2005).
-
(2005)
J. Immunol.
, vol.174
, Issue.6
, pp. 3187-3196
-
-
Tangri, S.1
Mothe, B.R.2
Eisenbraun, J.3
-
61
-
-
2442661578
-
Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope
-
Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172(11), 6658-6665 (2004).
-
(2004)
J. Immunol.
, vol.172
, Issue.11
, pp. 6658-6665
-
-
Yeung, V.P.1
Chang, J.2
Miller, J.3
Barnett, C.4
Stickler, M.5
Harding, F.A.6
-
62
-
-
0036218529
-
Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling
-
Warmerdam PA, Plaisance S, Vanderlick K et al. Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb. Haemost. 87(4), 666-673 (2002).
-
(2002)
Thromb. Haemost.
, vol.87
, Issue.4
, pp. 666-673
-
-
Warmerdam, P.A.1
Plaisance, S.2
Vanderlick, K.3
-
63
-
-
84873587155
-
Structure-guided de immunization of therapeutic proteins
-
Parker AS, Choi Y, Griswold KE, Bailey-Kellogg C. Structure-guided de immunization of therapeutic proteins. J. Comput. Biol. 20(2), 152-165 (2013).
-
(2013)
J. Comput. Biol.
, vol.20
, Issue.2
, pp. 152-165
-
-
Parker, A.S.1
Choi, Y.2
Griswold, K.E.3
Bailey-Kellogg, C.4
-
64
-
-
84880911013
-
The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix
-
Moise L, Gutierrez AH, Bailey-Kellogg C et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum. Vaccin. Immunother. 9(7), 1577-1586 (2012).
-
(2012)
Hum. Vaccin. Immunother.
, vol.9
, Issue.7
, pp. 1577-1586
-
-
Moise, L.1
Gutierrez, A.H.2
Bailey-Kellogg, C.3
-
65
-
-
84878135799
-
Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes
-
Cousens LP, Su Y, McClaine E et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. 621693 (2013).
-
(2013)
J. Diabetes Res.
, pp. 621693
-
-
Cousens, L.P.1
Su, Y.2
McClaine, E.3
-
66
-
-
84883741462
-
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
-
doi:10.1038/ mt.2013.166 (Epub ahead of print).
-
Hui DJ, Basner-Tschakarjan E, Chen Y et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol. Ther. doi:10.1038/ mt.2013.166 (2013) (Epub ahead of print).
-
(2013)
Mol. Ther.
-
-
Hui, D.J.1
Basner-Tschakarjan, E.2
Chen, Y.3
-
67
-
-
84872403415
-
Tregitope update: Mechanism of action parallels IVIg
-
Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Tregitope update: mechanism of action parallels IVIg. Autoimmun. Rev. 12(3), 436-443 (2012).
-
(2012)
Autoimmun. Rev.
, vol.12
, Issue.3
, pp. 436-443
-
-
Cousens, L.P.1
Tassone, R.2
Mazer, B.D.3
Ramachandiran, V.4
Scott, D.W.5
De Groot, A.S.6
-
68
-
-
79958264390
-
Vaccination with patient-specific tumorderived antigen in first remission improves disease-free survival in follicular lymphoma
-
Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumorderived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.20
, pp. 2787-2794
-
-
Schuster, S.J.1
Neelapu, S.S.2
Gause, B.L.3
-
69
-
-
38349191376
-
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis
-
Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111(2), 715-722 (2008).
-
(2008)
Blood
, vol.111
, Issue.2
, pp. 715-722
-
-
Ephrem, A.1
Chamat, S.2
Miquel, C.3
-
70
-
-
84860751767
-
High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis
-
Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 39(5), 1019-1025 (2012).
-
(2012)
J. Rheumatol.
, vol.39
, Issue.5
, pp. 1019-1025
-
-
Tsurikisawa, N.1
Saito, H.2
Oshikata, C.3
Tsuburai, T.4
Akiyama, K.5
-
71
-
-
33749259809
-
A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells
-
Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J. Am. Soc. Nephrol. 17(10), 2844-2853 (2006).
-
(2006)
J. Am. Soc. Nephrol.
, vol.17
, Issue.10
, pp. 2844-2853
-
-
Lopez, M.1
Clarkson, M.R.2
Albin, M.3
Sayegh, M.H.4
Najafian, N.5
-
72
-
-
84875410765
-
Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat
-
Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13(3), 176-89 (2013).
-
(2013)
Rev. Immunol.
, vol.13
, Issue.3
, pp. 176-89
-
-
Schwab, I.1
Nimmerjahn, F.2
-
73
-
-
84883268937
-
Immune responses to AAV vectors: Overcoming barriers to successful gene therapy
-
Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1), 23-36 (2013).
-
(2013)
Blood
, vol.122
, Issue.1
, pp. 23-36
-
-
Mingozzi, F.1
High, K.A.2
-
74
-
-
84886245403
-
Tolerance induction in hemophilia A animal models: Battling inhibitors with antigen-specific immunotherapies
-
Adair P, Su Y, Scott DW. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies. Discov. Med. 15(84), 275-282 (2013).
-
(2013)
Discov. Med.
, vol.15
, Issue.84
, pp. 275-282
-
-
Adair, P.1
Su, Y.2
Scott, D.W.3
-
75
-
-
0037364804
-
Natural versus adaptive regulatory T cells
-
Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3, 253-257 (2003).
-
(2003)
Nat. Rev. Immunol.
, vol.3
, pp. 253-257
-
-
Bluestone, J.A.1
Abbas, A.K.2
-
76
-
-
84862270750
-
Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)
-
Bakacs T, Mehrishi JN, Szabo M, Moss RW. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). Pharmacol. Res. 66(2), 192-197 (2012).
-
(2012)
Pharmacol. Res.
, vol.66
, Issue.2
, pp. 192-197
-
-
Bakacs, T.1
Mehrishi, J.N.2
Szabo, M.3
Moss, R.W.4
-
77
-
-
0022502731
-
Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function
-
Baxevanis CN, Ioannides CG, Reclos GJ, Papamichail M. Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function. Eur. J. Immunol. 16, 1013-1016 (1986).
-
(1986)
Eur. J. Immunol.
, vol.16
, pp. 1013-1016
-
-
Baxevanis, C.N.1
Ioannides, C.G.2
Reclos, G.J.3
Papamichail, M.4
-
78
-
-
0029995883
-
Epitope-specific tolerance induction with an engineered immunoglobulin
-
Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc. Natl Acad. Sci. U.S. A. 93, 5019-5024 (1996).
-
(1996)
Proc. Natl Acad. Sci. U.S. A.
, vol.93
, pp. 5019-5024
-
-
Zambidis, E.T.1
Scott, D.W.2
-
80
-
-
33751106428
-
IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris
-
Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 39(70), 601-607 (2006).
-
(2006)
Autoimmunity
, vol.39
, Issue.70
, pp. 601-607
-
-
Bystryn, J.C.1
Jiao, D.2
-
81
-
-
33644927503
-
Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients
-
Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am. J. Transplant. 6(3), 459-466 (2006).
-
(2006)
Am. J. Transplant.
, vol.6
, Issue.3
, pp. 459-466
-
-
Jordan, S.C.1
Vo, A.A.2
Peng, A.3
Toyoda, M.4
Tyan, D.5
-
82
-
-
84878344070
-
Alemtuzumab treatment of multiple sclerosis
-
Coles AJ. Alemtuzumab treatment of multiple sclerosis. Semin. Neurol. 33(1), 66-73 (2013).
-
(2013)
Semin. Neurol.
, vol.33
, Issue.1
, pp. 66-73
-
-
Coles, A.J.1
-
83
-
-
77956209762
-
A novel strategy to reduce the immunogenicity of biological therapies
-
Somerfield J, Hill-Cawthorne GA, Lin A et al. A novel strategy to reduce the immunogenicity of biological therapies. J. Immunol. 185(1), 763-768 (2010).
-
(2010)
J. Immunol.
, vol.185
, Issue.1
, pp. 763-768
-
-
Somerfield, J.1
Hill-Cawthorne, G.A.2
Lin, A.3
-
84
-
-
0026783632
-
Humanised monoclonal antibody therapy for rheumatoid arthritis
-
Isaacs JD, Watts RA, Hazleman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340(8822), 748-752 (1992).
-
(1992)
Lancet
, vol.340
, Issue.8822
, pp. 748-752
-
-
Isaacs, J.D.1
Watts, R.A.2
Hazleman, B.L.3
-
85
-
-
0029875268
-
CAMPATH-1H in rheumatoid arthritis: An intravenous dose-ranging study
-
Isaacs JD, Manna VK, Rapson N et al. CAMPATH-1H in rheumatoid arthritis: an intravenous dose-ranging study. Br. J. Rheumatol. 35(3), 231-240 (1996).
-
(1996)
Br. J. Rheumatol.
, vol.35
, Issue.3
, pp. 231-240
-
-
Isaacs, J.D.1
Manna, V.K.2
Rapson, N.3
-
86
-
-
0029143898
-
Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection
-
Matteson EL, Yocum DE, St Clair EW et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 38(9), 1187-1193 (1995).
-
(1995)
Arthritis Rheum.
, vol.38
, Issue.9
, pp. 1187-1193
-
-
Matteson, E.L.1
Yocum, D.E.2
St Clair, E.W.3
|